evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

10 questions · 10 findings · 1 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 40%Moderate 6 · 60%High 0 · 0%

LAMA vs LABA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LAMA

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LAMA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).

1 finding from 1 review

LABA/LAMA vs LABA

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/ICS vs LAMA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).

1 finding from 1 review